




Second Quarter 2026 Financial Results

August 7, 2026



Disclaimer

Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the “Company,” “Certara,” “we,” “us,” and “our” refer to Certara, Inc. and its consolidated subsidiaries.

Trademarks and Service Marks

The Certara design logo, “Certara,” and our other registered or common law trademarks, service marks or trade names appearing in this presentation are our property. Solely for convenience, our trademarks, tradenames, and service marks referred to in this presentation appear without the registered mark or trademark symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, tradenames, and service marks. This presentation contains additional trademarks, tradenames, and service marks of other companies that are the property of their respective owners. We do not intend our use or display of other companies’ trademarks, trade names or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, that reflect the Company’s current views with respect to, among other things, the Company’s operations and financial performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “targets,” “projections,” “should,” “could,” “would,” “may,” “might,” “will,” and other similar expressions. We base these forward-looking statements or projections on our current expectations, plans and assumptions, which we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development; the Company’s ability to compete within its market; changes or delays in government regulation relating to the biopharmaceutical industry; trends in research and development spending; operational disruptions, funding constraints and policy changes at the Food and Drug Administration and other government agencies; consolidation within the biopharmaceutical industry; the Company’s ability to increase successfully its customer base, expand relationships and the products and services it provides and enter new markets; , and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings and reports, including the Annual Report on Form 10-K filed with the SEC on February 26, 2026 and subsequent reports. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and is expressly qualified in its entirety by the cautionary statements included in this presentation. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws. You should not place undue reliance on our forward-looking statements.

Non-GAAP Financial Information


This presentation contains “non-GAAP measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, we may make use of the non-GAAP financial measures adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted diluted earnings per share (“EPS”), and constant currency (“CC”) revenue, which are not recognized terms under GAAP and should not be considered as alternatives to net income (loss), GAAP EPS, or GAAP revenue as measures of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. These non-GAAP measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

Adjusted EBITDA represents net income (loss) excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense and other items not indicative of our ongoing operating performance. Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. Adjusted net income and adjusted diluted EPS exclude the effect of the same items noted above with respect to adjusted EBITDA from GAAP net income (loss) and GAAP EPS, respectively, as well as adjust the provision for income taxes for such charges. CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. dollars are converted into U.S. dollars at the average exchange rates in effect for the comparable prior periods. You should refer to the appendix at the end of this document for a reconciliation of these non-GAAP measures in specific periods to their most directly comparable financial measures calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income from operations, net income, CC revenue and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance. Management believes that these metrics are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance. In addition, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We use CC revenue to evaluate the underlying performance of the business, and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance. In evaluating adjusted EBITDA, adjusted net income (loss), adjusted diluted EPS, and CC revenue, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.

Financial Highlights

Second Quarter 2026 from Continuing Operations




(1) See Appendix for reconciliation of net income (loss) to adjusted EBITDA

(2) See Appendix for reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share

2Q 2026 Results - Revenue

GAAP Reported Revenue from Continuing Operations

(\$Millions)




Certara reported 1% revenue growth during the Second Quarter

2Q 2026 and TTM Results - Net Bookings

Excluding the Regulatory and Medical Writing Business


2Q Reported Net Bookings

(\$Millions)



TTM Reported Net Bookings


(\$Millions)



Trailing twelve-month bookings were up 3% vs. the prior year period


Historical TTM Book to Bill

Excluding the Regulatory and Medical Writing Business



Book to bill provides forward visibility into revenue growth

2Q 2026 Results – Adjusted EBITDA



2Q26 Adjusted EBITDA declined (3%) vs. the prior year period

(1) See Appendix for a reconciliation net income (loss) to adjusted EBITDA
(2) Adjusted EBITDA margin reflects residual shared corporate costs retained following the divestiture of the Regulatory and Medical Writing business.

2Q26 Business Updates

Key Takeaways from Second Quarter 2026:




Closed Divestiture of Regulatory & Medical Writing

- Sold business to Veristat for a consideration of up to \$135M. Revenue mix now approximately 50/50 software and services.
- Divestiture will sharpen our execution in areas where we have a defined competitive and scientific advantage.



2Q Performance In-Line with Plan

- Total revenue was in-line with expectations, with software growth offsetting softer performance in services.
- Software bookings momentum continues to build, with TTM growth accelerating versus the prior year's exit rate.
- Our customer-centric go-to-market model is showing traction following the reorganization.




AI Innovation and Leadership

- Collaboration with NVIDIA, integrating the BioNeMo Agent Toolkit into Certara's next-generation platform.
- Preparing for the beta launch of our first AI platform module, creating smart connections across existing products.
- Named Julien Perrier as CCO and promoted Eric Jahn to CIO and Faiz Mohammed to Interim CFO

2026 Outlook

FY 2026 guidance for Continuing Operations



Financial results of the Regulatory and Writing business will be reported as discontinued operations for 2026. Through the transaction closing on May 8th, the year-to-date discontinued operations Revenue was \$19.2 million.

This financial guidance is provided as of August 4, 2026, and its inclusion in this presentation should not be construed as continued affirmation of such guidance beyond that date.

(1) We have not reconciled the adjusted EBITDA margin and adjusted diluted EPS forward-looking guidance above to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.


Key Assumptions 2026 Guidance

Ex-regulatory revenue growth of
0-4%

Fully diluted shares expected to be
in the range of **155-157M**

Tax rate expected to be
approximately **30%**

Appendix



Regulatory and Medical Writing – Supplemental Information

On April 22nd, 2026, Certara announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to \$135 million. The transaction closed on May 8th, 2026.

Historical Regulatory and Medical Writing Revenue

1Q24	2Q24	3Q24	4Q24	FY24	1Q25	2Q25	3Q25	4Q25	FY25
\$12.9M	\$13.4M	\$14.9M	\$14.1M	\$55.3M	\$13.9M	\$12.2M	\$13.7M	\$12.0M	\$51.8M

In 2025, the Regulatory and Medical Writing business generated \$52 million in revenue, and \$17 million in adjusted EBITDA, including unallocated corporate expense that will remain with the company; the 2025 adjusted EBITDA generated by the Regulatory and Medical Writing business, excluding unallocated corporate expense that will remain with the Company, is \$23 million.

Reconciliation of Net Income (Loss) to Adjusted EBITDA

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2026	2025	2026	2025
	(in thousands)			
Net income (loss) from continuing operations(a)	\$ (6,081)	\$ 1,496	\$ (17,906)	\$ 3,001
Interest expense(a)	4,987	4,802	9,928	9,608
Interest income(a)	(943)	(1,243)	(2,069)	(2,885)
(Benefit from) Provision for income taxes(a)	(307)	2,874	1,614	2,583
Intangible asset amortization and fixed assets depreciation(a)	16,329	15,733	32,342	31,271
Currency (gain) loss(a)	2,358	(577)	2,418	(639)
Equity-based compensation expense(b)	6,094	8,245	13,414	15,315
Change in fair value of contingent consideration(d)	—	(5,722)	7,230	(5,901)
Acquisition-related (income) expenses(e)	(132)	428	(114)	1,304
Reorganization expense(f)	3,182	934	4,187	1,085
Loss (gain) on disposal of fixed assets(g)	(24)	(1)	(14)	5
Executive recruiting expense(h)	735	—	1,851	661
Adjusted EBITDA	<u>\$ 26,198</u>	<u>\$ 26,969</u>	<u>\$ 52,881</u>	<u>\$ 55,408</u>

Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2026	2025	2026	2025
	(in thousands)			
Net income (loss) from continuing operations(a)	\$ (6,081)	\$ 1,496	\$ (17,906)	\$ 3,001
Currency (gain) loss(a)	2,358	(577)	2,418	(639)
Equity-based compensation expense(b)	6,094	8,245	13,414	15,315
Amortization of acquisition-related intangible assets(c)	10,849	10,947	21,640	21,938
Change in fair value of contingent consideration(d)	—	(5,722)	7,230	(5,901)
Acquisition-related (income) expenses(e)	(132)	428	(114)	1,304
Reorganization expense(f)	3,182	934	4,187	1,085
Loss (gain) on disposal of fixed assets(g)	(24)	(1)	(14)	5
Executive recruiting expense(h)	735	—	1,851	661
Income tax expense impact of adjustments(i)	(4,441)	(3,023)	(11,132)	(7,319)
Adjusted net income	<u>\$ 12,540</u>	<u>\$ 12,727</u>	<u>\$ 21,574</u>	<u>\$ 29,450</u>

Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2026	2025	2026	2025
Diluted earnings per share from continuing operations (a)	\$ (0.04)	\$ 0.01	\$ (0.11)	\$ 0.02
Currency (gain) loss(a)	0.02	-	0.02	-
Equity-based compensation expense(b)	0.04	0.05	0.08	0.09
Amortization of acquisition-related intangible assets(c)	0.07	0.07	0.13	0.14
Change in fair value of contingent consideration(d)	-	(0.04)	0.05	(0.04)
Acquisition-related expenses(e)	-	-	-	0.01
Reorganization expense(f)	0.02	0.01	0.03	0.01
Loss (gain) on disposal of fixed assets(g)	-	-	-	-
Executive recruiting expense(h)	-	-	0.01	-
Income tax expense impact of adjustments(i)	(0.03)	(0.02)	(0.07)	(0.05)
Adjusted diluted earnings per share	<u>\$ 0.08</u>	<u>\$ 0.08</u>	<u>\$ 0.14</u>	<u>\$ 0.18</u>
Basic weighted average common shares outstanding	154,356,779	160,916,057	156,046,326	160,955,936
Effect of potentially dilutive shares outstanding (j)	<u>595,507</u>	<u>932,945</u>	<u>433,412</u>	<u>645,088</u>
Adjusted diluted weighted average common shares outstanding	<u>154,952,286</u>	<u>161,849,002</u>	<u>156,479,738</u>	<u>161,601,024</u>

Notes to Reconciliations

- a) Represents a measure determined under GAAP.
- b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
- c) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.
- d) Represents expense associated with fair value adjustment or adjustment of contingent consideration of business acquisition.
- e) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.
- f) Represents expenses related to reorganization, including legal entity reorganization and lease abandonment costs associated with the evaluation of our office space footprint.
- g) Represents the gain/loss related to disposal of fixed assets.
- h) Represents recruiting, relocation expenses, and retention costs related to senior executives.
- i) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.
- j) Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.



Accelerating Medicines, Together

